Skip to content

Joy Krecké

4 papers in the library · 43 citations · publishing 2024-2025

Papers

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems.

Journal of psychopharmacology (Oxford, England) June 1, 2024 Emily M Gent, Joshua W Bryan, Maisy A Cleary et al. 20 citations

A double-blind pilot study tested whether a single dose of esketamine, combined with two weeks of daily mindfulness-based intervention (MBI), enhances engagement in meditation and improves alcohol-related outcomes among 28 individuals with alcohol problems. Participants received either sublingual esketamine (115.1 mg) or a vitamin C placebo. Esketamine increased psychological engagement with daily MBI and produced transient decreases in alcohol cravings, along with greater mystical experiences and dissociative states compared to placebo. The findings suggest that esketamine may improve treatment outcomes when paired with mindfulness-based therapies by boosting engagement with meditative practice.

On Minimizing Risk and Harm in the Use of Psychedelics.

Psychiatr Res Clin Pract February 11, 2025 Jules Evans, Marc Aixalà, Brian T. Anderson et al. 18 citations

Thirty psychedelic researchers identified critical gaps in knowledge about harms from psychedelic use, including how to define those harms, predict them, and treat them effectively. They recommend better online information, peer support groups, affordable therapy, and psychiatric consultation for people experiencing post-psychedelic difficulties. The researchers also call for improved funding for a psychedelic safety net, suggesting that psychedelic philanthropists, investors, and companies commit 1% of their investment to support safety measures such as research and support services. The article outlines practical steps to make the field of psychedelic medicine safer.

The rising use of cognitive enhancement drugs and predictors of use during COVID-19: findings from a cross-sectional survey of students and university staff in the UK.

Frontiers in psychology January 1, 2024 Jamie L Tully, Oliver Bridge, Joseph Rennie et al. 3 citations

During the first year of COVID-19 social restrictions (March 2020–February 2021), use of psychoactive substances for cognitive enhancement rose significantly among UK university students and staff compared to the previous year. Modafinil use increased by 42%, nutraceuticals by 30.2%, and microdose LSD by 22.2%. Polydrug use with modafinil and other prescription stimulants also rose. Personality factors—particularly lower agreeableness, male gender identity, and lower conscientiousness—reliably predicted use, while academic self-efficacy and student/staff status did not. The authors suggest increased pressures from lockdown and reduced access to university resources drove the rise.

Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: A qualitative analysis

Research Square May 13, 2025 Eirini K. Argyri, Joy Krecké, Oliver Robinson et al. 2 citations

Professionals who support people after psychedelic experiences identify six common extended difficulties: existential struggle and ontological shock, anxiety and panic, self-perception issues, dissociative symptoms, resurfacing of repressed trauma, and disappointment from unmet expectations. Recommended support strategies include trauma-informed individual psychotherapy, grounding and mindfulness techniques, peer and community support, meaning-making and narrative reconstruction, and sometimes short-term psychiatric medication. Psychiatrists emphasize medical stabilization, while psychotherapists and coaches focus on existential meaning-making and emotional processing. The findings suggest that trauma-informed, cross-disciplinary approaches are needed for psychedelic integration as use expands.